Literature DB >> 10201970

Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.

J E Buhlmann1, M Gonzalez, B Ginther, A Panoskaltsis-Mortari, B R Blazar, D L Greiner, A A Rossini, R Flavell, R J Noelle.   

Abstract

Brief treatment with alphaCD154 Ab has been shown to prevent acute graft versus host disease (aGvHD). We extend these data to show that in the absence of CD154 function, donor T cells are unable to expand or generate high level anti-host CTL activity. Using transgenic (Tg) alloreactive CD8+ T cells adoptively transferred into allogeneic recipients, we show that short-term expansion of the CD8+ Tg T cells occurred in the absence of Th cells, and this short-term expansion could be facilitated with an agonistic alphaCD40. While CD40 agonism could enhance short-term expansion, sustained expansion of CD8+ Tg T cells required bona fide CD154-expressing CD4+ alloreactive Th cells. While CD154 was necessary for CD8+ Tg T cell sustained expansion, IL-2 was also implicated as essential. These observations suggest alphaCD154 therapy in GvHD is effective because the treatment causes an abortive CD8 alloresponse leading to the exhaustion or deletion of alloreactive CD8+ clones preventing the development of disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201970

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Inhibition of B-cell death does not restore T-cell-dependent immune responses in CD40-deficient mice.

Authors:  Jesús Merino; Miguel A Díez; María Muñiz; Luis Buelta; Gabriel Núñez; Marcos López-Hoyos; Ramón Merino
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

4.  Deletion of Fanca or Fancd2 dysregulates Treg in mice.

Authors:  Wei Du; Ozlem Erden; Andrew Wilson; Jared M Sipple; Jonathan Schick; Parinda Mehta; Kasiani C Myers; Kris A Steinbrecher; Stella M Davies; Qishen Pang
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

Review 5.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 6.  Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

Authors:  H J Deeg
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

7.  Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.

Authors:  J Ohata; J Sakurai; K Saito; K Tani; S Asano; M Azuma
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

8.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

Review 9.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

10.  Mast cell degranulation breaks peripheral tolerance.

Authors:  V C de Vries; A Wasiuk; K A Bennett; M J Benson; R Elgueta; T J Waldschmidt; R J Noelle
Journal:  Am J Transplant       Date:  2009-07-22       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.